| Literature DB >> 29340037 |
Jian Wu1, Zheng-Ping Chen2, An-Quan Shang3, Wei-Wei Wang4, Zong-Ning Chen1, Yun-Juan Tao5, Yue Zhou5, Wan-Xiang Wang1.
Abstract
Recurrent aphthous stomatitis (RAS) represents the most common chronic oral diseases with the prevalence ranges from 5% to 25% for different populations. Its pathogenesis remains poorly understood, which limits the development of effective drugs and treatment methods. In this study, we conducted systemic bioinformatics analysis of gene expression profiles from the Gene Expression Omnibus (GEO) to identify potential drug targets for RAS. We firstly downloaded the gene microarray datasets with the accession number of GSE37265 from GEO and performed robust multi-array (RMA) normalization with affy R programming package. Secondly, differential expression genes (DEGs) in RAS samples compared with control samples were identified based on limma package. Enriched gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of DEGs were obtained through the Database for Annotation, Visualization and Integrated Discovery (DAVID). Finally, protein-protein interaction (PPI) network was constructed based on the combination of HPRD and BioGrid databases. What's more, we identified modules of PPI network through MCODE plugin of Cytoscape for the purpose of screening of valuable targets. As a result, 915 genes were found to be significantly differential expression in RAS samples and biological processes related to immune and inflammatory response were significantly enriched in those genes. Network and module analysis identified FBXO6, ITGA4, VCAM1 and etc as valuable therapeutic targets for RAS. Finally, FBXO6, ITGA4, and VCAM1 were further confirmed by real time RT-PCR and western blot. This study should be helpful for the research and treatment of RAS.Entities:
Keywords: RAS; gene expression omnibus (GEO); immune; limma; visualization and integrated discovery (DAVID)
Year: 2017 PMID: 29340037 PMCID: PMC5762305 DOI: 10.18632/oncotarget.22347
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Overall mRNA level of all probesets in the microarray after normalized through affy package
The normalized expression values are comparable among all of the samples which should be suitable for the following analysis.
The top 20 GO terms of DEGs according to P value
| Category | GOID | GO Name | Gene Number | Pvalue |
|---|---|---|---|---|
| BP | GO:0006955 | immune response | 180 | 4.25E-84 |
| BP | GO:0006952 | defense response | 137 | 1.41E-53 |
| BP | GO:0009611 | response to wounding | 105 | 1.09E-35 |
| BP | GO:0006954 | inflammatory response | 82 | 1.50E-35 |
| CC | GO:0044421 | extracellular region part | 138 | 8.00E-29 |
| CC | GO:0005576 | extracellular region | 214 | 6.49E-27 |
| CC | GO:0005615 | extracellular space | 109 | 3.63E-26 |
| BP | GO:0002684 | positive regulation of immune system process | 60 | 6.30E-26 |
| BP | GO:0006935 | chemotaxis | 44 | 1.18E-20 |
| BP | GO:0042330 | taxis | 44 | 1.18E-20 |
| BP | GO:0050778 | positive regulation of immune response | 42 | 1.20E-20 |
| BP | GO:0001775 | cell activation | 58 | 4.74E-20 |
| BP | GO:0048584 | positive regulation of response to stimulus | 52 | 1.02E-19 |
| BP | GO:0045321 | leukocyte activation | 52 | 3.21E-19 |
| BP | GO:0009615 | response to virus | 34 | 7.35E-18 |
| BP | GO:0042110 | T cell activation | 33 | 7.11E-15 |
| BP | GO:0050867 | positive regulation of cell activation | 31 | 8.07E-15 |
| BP | GO:0046649 | lymphocyte activation | 41 | 1.59E-14 |
| BP | GO:0045087 | innate immune response | 34 | 1.78E-14 |
| MF | GO:0005125 | cytokine activity | 40 | 2.47E-14 |
The KEGG pathways of DEGs
| Category | Pathway Name | Gene Number | Pvalue |
|---|---|---|---|
| KEGG_PATHWAY | Cytokine-cytokine receptor interaction | 55 | 1.07E-14 |
| KEGG_PATHWAY | Graft-versus-host disease | 18 | 8.65E-11 |
| KEGG_PATHWAY | Allograft rejection | 17 | 2.21E-10 |
| KEGG_PATHWAY | Type I diabetes mellitus | 18 | 3.59E-10 |
| KEGG_PATHWAY | Cell adhesion molecules (CAMs) | 31 | 1.18E-09 |
| KEGG_PATHWAY | Toll-like receptor signaling pathway | 26 | 4.72E-09 |
| KEGG_PATHWAY | Natural killer cell mediated cytotoxicity | 29 | 2.65E-08 |
| KEGG_PATHWAY | Hematopoietic cell lineage | 22 | 1.09E-07 |
| KEGG_PATHWAY | Chemokine signaling pathway | 34 | 1.38E-07 |
| KEGG_PATHWAY | Antigen processing and presentation | 21 | 2.78E-07 |
| KEGG_PATHWAY | Viral myocarditis | 19 | 4.93E-07 |
| KEGG_PATHWAY | Intestinal immune network for IgA production | 15 | 2.01E-06 |
| KEGG_PATHWAY | Autoimmune thyroid disease | 14 | 1.85E-05 |
| KEGG_PATHWAY | Systemic lupus erythematosus | 20 | 2.03E-05 |
| KEGG_PATHWAY | Jak-STAT signaling pathway | 26 | 2.49E-05 |
| KEGG_PATHWAY | Complement and coagulation cascades | 16 | 3.35E-05 |
| KEGG_PATHWAY | NOD-like receptor signaling pathway | 15 | 3.91E-05 |
| KEGG_PATHWAY | Cytosolic DNA-sensing pathway | 13 | 1.98E-04 |
| KEGG_PATHWAY | T cell receptor signaling pathway | 19 | 2.27E-04 |
| KEGG_PATHWAY | Primary immunodeficiency | 10 | 3.42E-04 |
| KEGG_PATHWAY | Leukocyte transendothelial migration | 19 | 6.92E-04 |
| KEGG_PATHWAY | ECM-receptor interaction | 14 | 0.003302 |
| KEGG_PATHWAY | B cell receptor signaling pathway | 11 | 0.025533 |
| KEGG_PATHWAY | Fc gamma R-mediated phagocytosis | 12 | 0.049062 |
Figure 2Significantly enriched KEGG pathways and corresponding DEG number contained in them
The modules we obtained from the PPI network
| Module ID | Scorea | Nodesb | Edgesc | Genes |
|---|---|---|---|---|
| 1 | 2.154 | 13 | 28 | CD5, FCGR2A, FYN, IL7R, LAT, LCK, LYN,PIK3R1, PLCG2, SLA, SYK, TRAT1, WA |
| 2 | 1.894 | 66 | 125 | ABL1, ACTB, BRCA1, C1QB, C1QC, CCR5, CD247, CD82, CREBBP, CXCR4, CYBA, CYBB, EGFR, F2, FLNA, GNB2L1, GRB2, HCK, HNRNPA2B1, HNRNPM, ICAM1, IFNAR2, ILF3, ITGA4, ITGAL, ITGB1, ITGB2, KIT, NCF1, NCF2, NPM1, PABPC1, PECAM1, PLAU, PLCG1, PLG, POMP, PSMA4, PSMB1, PSMB10, PSMB3, PSMB7, PSMB8, PSMB9, PSMC5, PSME2, PTK2B, PTX3, RAC2, RANBP9, RELA, RPL13A, SERPINE1, SF1, SH2D2A, SHC1, SLC2A1, SNRPD1, SNRPD3, SOCS3, STAT2, STAT3, STAT5A, STOM, THBS1, YBX1 |
| 3 | 1.561 | 25 | 39 | ACAN, AR, BIRC3, BIRC5, CASP1, CASP7, CCBP2, CCL5, CCL7, CCL8, CCR3, CEBPB, CXCL10, DCN, DPP4, MMP1, MMP3, NOD2, PSEN2, RB1, RIPK2, RPS6KA1, SUMO1, TNF, TNFRSF1A |
| 4 | 1.522 | 12 | 18 | COL1A2, COL4A1, COL4A2, HSP90AA1, IRF7, IRF8, LGALS3BP, SGK1, TGFBI, TRIM21, UBC, WNK4 |
| 5 | 1.514 | 6 | 9 | FADD, RIPK1, TNFAIP3, TNFRSF10B, TNFSF10, TRAF2 |
Note: a: The score of a module
b: The number of genes in the module
c: The number of interactions in the module
Figure 3Modules of PPI network obtained through MCODE plugin of Cytoscape
Red and green nodes represent DEGs and non differential expression genes respectively.
Figure 4Validation of FBXO6, ITGA4 and VCAM1 through qPCR and Western blot
(A), (B) and (C) is the relative mRNA level of FBXO6, ITGA4 and VCAM1 quantified by qPCR respectively. (D) Protein abundance of FBXO6, ITGA4 and VCAM1 detected by Western blot.